raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
Published 2 years ago • 2.1K plays • Length 1:09:24Download video MP4
Download video MP3
Similar videos
-
32:54
raising the bar in her2-positive breast cancer
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
55:30
breaking down barriers to treatment adherence and persistence in hr /her2- early breast cancer
-
29:21
new advances and opportunities for improvement in hr /her2- early breast cancer
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
1:33:57
evaluating the evidence and parsing the practicalities of therapeutic choices in hr breast cancer
-
1:31:37
personalizing treatment decisions in her2-altered breast cancer
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
1:40:47
clarifyingcomplexities of expandingtreatmentoptionsfor advancedandearly-stage hr /her2- breastcancer
-
19:30
empowering choices: navigating early-stage hr , her2- breast cancer with cdk4/6 inhibition
-
1:02:43
realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
5:16
cdk4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in hr-positive/her2-nega...
-
40:56
new horizons in high-risk hr her2- ebc: risk stratification for early identification
-
4:02
the spectrum of hr breast cancer: approaching treatment
-
4:39
case 1: approach to early stage, her2 breast cancer